- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CD166 Antibody rMOG/07 / ALCAM Monoclonal Antibody targets activated leukocyte cell adhesion molecule (ALCAM), a transmembrane glycoprotein belonging to the immunoglobulin superfamily. Also designated CD166, ALCAM mediates interactions between neighboring cells and contributes to the organization of tissues, immune cell communication, and cellular migration. Its expression in diverse cell populations reflects the importance of regulated adhesion during development, tissue maintenance, and responses to changes in the cellular environment.
ALCAM contains five extracellular immunoglobulin-like domains, a single transmembrane segment, and a short cytoplasmic region. The extracellular domains support homophilic interactions between ALCAM molecules on adjacent cells and heterophilic binding to CD6, a receptor expressed predominantly on T lymphocytes. These interactions contribute to the stabilization of intercellular contacts and help coordinate communication between immune cells and other cellular populations. The ALCAM-CD6 interaction has attracted particular interest because adhesion influences the duration and organization of contacts involved in immune activation.
Cellular adhesion mediated by ALCAM is dynamically regulated rather than permanently fixed. Interactions with cytoskeletal-associated proteins influence the distribution and clustering of ALCAM at the plasma membrane, affecting the strength and organization of adhesive contacts. The protein also undergoes extensive N-linked glycosylation, contributing to its mature molecular properties. Proteolytic cleavage of the extracellular region can generate soluble ALCAM, providing another mechanism through which its cell-surface abundance and adhesive functions may be regulated.
ALCAM participates in developmental processes requiring coordinated cellular movement and recognition. Its expression has been investigated in neural development, epithelial organization, endothelial interactions, and the regulation of contacts between hematopoietic cells. Changes in ALCAM distribution can influence how cells maintain tissue architecture while retaining the ability to migrate or reorganize in response to developmental and environmental signals.
In cancer biology, altered ALCAM expression and localization have been associated with changes in tumor cell adhesion, invasion, and interactions with surrounding tissues. Its relationship with tumor progression is context-dependent, and differences in expression do not necessarily indicate identical biological behavior across malignancies. CD166 Antibody rMOG/07 supports research into the distribution and regulation of this adhesion molecule, helping characterize the cellular interactions that influence tissue organization, immune communication, and tumor-associated adhesion.
For an alternative reagent with knockout validation and broader species reactivity, explore our ALCAM Antibody targeting CD166, a cell-surface glycoprotein involved in cell adhesion and immune interactions.
1. Optimal dilution of the CD166 Antibody rMOG/07 / ALCAM Monoclonal Antibody should be determined by the researcher.
2. This CD166/ALCAM antibody is recombinantly produced by expression in CHO cells.
The CD166/ALCAM antibody was raised against a 200 amino acid portion of human CD166.
CD166/ALCAM antibody with sodium azide - store at 2 to 8oC; antibody without sodium azide - store at -20 to -80oC.
Activated leukocyte cell adhesion molecule antibody, ALCAM antibody, CD166 cell adhesion molecule antibody, MEMD antibody, CD6 ligand antibody, ALCAM glycoprotein antibody, Activated leukocyte cell adhesion molecule CD166 antibody, ALCAM immunoglobulin superfamily protein antibody, CD166 cell surface protein antibody, ALCAM adhesion receptor antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.